Vorsitz: Z. Kaya (Heidelberg), O. Ritter (Würzburg)
(V963) | The PAR2 expression reduces the IFNβ expression in the heart |
A. Weithäuser, P. Bobbert, H. Zeichhardt, K. Savvatis, H.-P. Schultheiss, U. Rauch-Kröhnert (Berlin) | |
(V964) | The immune protein MD-2 is increased in serum of patients with dilated cardiomyopathy and stimulates cell specific directly the TLR4/NFkB pathway |
K. Neumann, M. Hundt, J. Witte, M. Dörr, K. Empen, K. Weitmann, W. Hoffmann, S. B. Felix, A. Riad (Greifswald) | |
(V965) | Protein modification with the ubiquitin-like modifier ISG15 prevents postviral dilated cardiomyopathy |
A. Voigt, A. Rahnefeld, A. Schürmann, P. Bleienheuft, K. Klingel, K.-P. Knobeloch, C. Tschöpe, P. M. Becher (Berlin, Tübingen, Freiburg im Breisgau) | |
(V966) | Mutations of the human BCL2-associated athanogene 3 (BAG3) gene result in a heart failure phenotype in zebrafish |
S. Westphal, A. Korniat, S. Just, E. Villard, P. Charron, H. A. Katus, W. Rottbauer (Ulm, Heidelberg; Paris, FR) | |
(V967) | Myosin mutations that cause hypertrophic cardiomyopathy exhibit synergistic effects |
R. Blankenburg, M. Lohse, C. Seidman, J. Seidman, J. Schmitt (Würzburg, Düsseldorf; Boston, US) | |
(V968) | A human heart muscle model of Noonan syndrome cardiomyopathy |
M. Tiburcy, T. Araki, S. Mital, B. G. Neel, G. Keller, W.-H. Zimmermann (Göttingen; Toronto, CA) |